Results 161 to 170 of about 8,361,399 (394)

Celebrating Our Seniors [PDF]

open access: yes, 2007
The Center hosted an event to celebrate the graduating seniorsDean of ...
Boston University Howard Thurman Center for Common Ground
core  

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

Cultural Jeopardy [PDF]

open access: yes, 2007
The Howard Thurman Center Student AmbassadorsBoston University's Chinese Student AssociationBoston University's UmojaBoston University's Korean Student AssociationBoston University's Minority Engineers SocietyBoston University's Japanese Student ...
Boston University Howard Thurman Center for Common Ground
core  

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira   +14 more
wiley   +1 more source

The ground state of embryonic stem cell self-renewal

open access: yesNature, 2008
Qi-Long Ying   +7 more
semanticscholar   +1 more source

FreeP talk: race & the media, in and out of the newsroom [PDF]

open access: yes, 2018
Panel discussion on race and the media - in and out of the newsroom, marketing materials main posterBoston University Howard Thurman Center for Common Ground, & The Daily Free ...
Boston University Howard Thurman Center for Common Ground
core  

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy